US EditionPublished • loading... • Updated
Samsung Bioepis Begins Direct Commercialization of Byooviz in Europe
Summary by Eyewire+
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Samsung Bioepis Begins Direct Commercialization of Byooviz in Europe
Samsung Bioepis has begun direct commercialization of Byooviz, a biosimilar to Lucentis (ranibizumab), across multiple European countries. The move follows the transfer of commercial rights from Biogen back to Samsung Bioepis. Byooviz will now be marketed as a Samsung Bioepis brand. Byooviz received European Commission (EC) approval in August 2021 as a single-use vial for intravitreal injection (0.5 mg/0.05 ml). It is approved for the treatment …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
